Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis - PubMed (original) (raw)
Review
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis
Kumlesh K Dev et al. Pharmacol Ther. 2008 Jan.
Abstract
Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS.
Similar articles
- Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V. Brinkmann V. Pharmacol Ther. 2007 Jul;115(1):84-105. doi: 10.1016/j.pharmthera.2007.04.006. Epub 2007 May 22. Pharmacol Ther. 2007. PMID: 17561264 Review. - Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW, Choi JW, Chun J. Lee CW, et al. Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Epub 2010 Oct 30. Arch Pharm Res. 2010. PMID: 21052934 Review. - Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Mehling M, et al. Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Neurology. 2011. PMID: 21339487 Review. - Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE, Schubart A, Antel JP. Miron VE, et al. J Neurol Sci. 2008 Nov 15;274(1-2):13-7. doi: 10.1016/j.jns.2008.06.031. Epub 2008 Aug 3. J Neurol Sci. 2008. PMID: 18678377 Review. - Fingolimod for relapsing multiple sclerosis: an update.
Horga A, Castilló J, Montalban X. Horga A, et al. Expert Opin Pharmacother. 2010 May;11(7):1183-96. doi: 10.1517/14656561003769866. Expert Opin Pharmacother. 2010. PMID: 20367536 Review.
Cited by
- Crosstalk between Fas and S1P1 signaling via NF-kB in osteoclasts controls bone destruction in the TMJ due to rheumatoid arthritis.
Hutami IR, Tanaka E, Izawa T. Hutami IR, et al. Jpn Dent Sci Rev. 2019 Nov;55(1):12-19. doi: 10.1016/j.jdsr.2018.09.004. Epub 2018 Oct 26. Jpn Dent Sci Rev. 2019. PMID: 30733840 Free PMC article. Review. - Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.
Pritchard AJ, Mir AK, Dev KK. Pritchard AJ, et al. PLoS One. 2014 Jun 9;9(6):e99444. doi: 10.1371/journal.pone.0099444. eCollection 2014. PLoS One. 2014. PMID: 24911000 Free PMC article. - S1P is associated with protection in human and experimental cerebral malaria.
Finney CA, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, Oravecz T, Liles WC, Kain KC. Finney CA, et al. Mol Med. 2011;17(7-8):717-25. doi: 10.2119/molmed.2010.00214. Epub 2011 May 5. Mol Med. 2011. PMID: 21556483 Free PMC article. - Ceramide signaling in cancer and stem cells.
Bieberich E. Bieberich E. Future Lipidol. 2008 Jun;3(3):273-300. doi: 10.2217/17460875.3.3.273. Future Lipidol. 2008. PMID: 19050750 Free PMC article. - AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Samuvel DJ, Saxena N, Dhindsa JS, Singh AK, Gill GS, Grobelny DW, Singh I. Samuvel DJ, et al. PLoS One. 2015 Oct 29;10(10):e0141781. doi: 10.1371/journal.pone.0141781. eCollection 2015. PLoS One. 2015. PMID: 26513477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources